|Bid||98.07 x 1000|
|Ask||98.20 x 800|
|Day's range||95.45 - 98.71|
|52-week range||72.67 - 141.86|
|Beta (5Y monthly)||1.38|
|PE ratio (TTM)||9.19|
|Earnings date||22 Apr 2020 - 26 Apr 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||141.05|
Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
We think intelligent long term investing is the way to go. But that doesn't mean long term investors can avoid big...
Alexion Pharmaceuticals, Inc. today announced that nine abstracts have been accepted for presentation at AAN.
Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the Cowen Health Care Conference in Boston, MA on Tuesday, March 3rd, 2020 at 9:20 a.m. ET.
Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the SVB Leerink Global Healthcare Conference in New York, NY on Tuesday, February 25th, 2020 at 9:30 a.m. ET.
Last week, you might have seen that Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) released its full-year result to the...
Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.
Alexion (ALXN) delivered earnings and revenue surprises of 3.44% and 1.72%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Acceleron (XLRN) stock surges as sotatercept meets primary and secondary endpoints in a phase II study in patients with pulmonary arterial hypertension.
On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales uptake of its CF drugs and the unveiling plans for the newly-approved Trikafta triple combination regimen.